Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 5/20 | 0.36 |
| ▸ | JAK2 | O60674 | 4/20 | 0.35 |
| ▸ | AXL | P30530 | 4/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.33 |
| ▸ | FEN1 | P39748 | 7/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28777665 | 1.00 | JAK1 (0.36) | JAK1JAK2AXLPIK3CDTYRO3 | |
| SCHEMBL28777660 | 1.00 | JAK1 (0.36) | JAK1JAK2AXLPIK3CDTYRO3 | |
| SCHEMBL22976454 | 0.88 | JAK2 (0.38) | JAK1JAK2AXLPIK3CDTYRO3 | |
| SCHEMBL22976139 | 0.88 | JAK2 (0.38) | JAK1JAK2AXLPIK3CDTYRO3 | |
| SCHEMBL22976138 | 0.88 | JAK2 (0.38) | JAK1JAK2AXLPIK3CDTYRO3 | |
| SCHEMBL22976361 | 0.88 | JAK2 (0.38) | JAK1JAK2AXLPIK3CDTYRO3 | |
| SCHEMBL29720010 | 0.88 | JAK2 (0.38) | JAK1JAK2AXLPIK3CDTYRO3 | |
| SCHEMBL28777487 | 0.86 | CYP11B2 (0.35) | RET | |
| SCHEMBL28777484 | 0.86 | CYP11B2 (0.35) | RET | |
| SCHEMBL28777488 | 0.86 | CYP11B2 (0.35) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114585614-A | Non-peptide somatostatin type 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2022-06-03 | — | — | CN | disclosed |